Soleno Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SLNO, updated each market day.
SLNO AI Sentiment
AI predicts Soleno Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Soleno Therapeutics, Inc. Common Stock
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
Sector
Exchange
Market Cap
$2,715,720,003
Cap Tier
Employees
182
Headquarters
REDWOOD CITY, CA
Listed Since
Nov. 13, 2014
Website
SLNO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SLNO Volatility
Soleno Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
